Literature DB >> 21335472

Aging attenuates the vasodilator response to relaxin.

Joris van Drongelen1, Ivo H J Ploemen, Jeanne Pertijs, Jonathan H Gooi, Fred C G J Sweep, Frederik K Lotgering, Marc E A Spaanderman, Paul Smits.   

Abstract

Relaxin, an insulin-like growth factor peptide, increases endothelium-dependent vasodilation and vascular compliance and decreases myogenic reactivity. These vascular effects significantly contribute to the physiological circulatory adaptations in pregnancy, particularly in the mesentery and kidney. Aging predisposes to vascular maladaptation and gestational hypertensive disease. We hypothesized that mild aging reduces the vascular responses to relaxin. In 20 young (10-12 wk) and 20 middle-aged (40-46 wk) female Wistar Hannover rats, vascular responses to chronic exposure of relaxin vs. placebo (5 days) were quantified in isolated mesenteric arteries and kidney. Vascular responses were evaluated using pressure-perfusion myograph, wire myograph, and an isolated perfused rat kidney model. Rxfp1 (relaxin family peptide) gene expression was determined by quantitative polymerase chain reaction. In young rats, relaxin stimulated nitric oxide (NO)-dependent flow-mediated vasodilation (2.67-fold, from 48 ± 9 to 18 ± 4 μl/min), reduced myogenic reactivity (from -1 ± 2 to 7 ± 3 μm/10 mmHg), and decreased mesenteric sensitivity to (28%, from 1.39 ± 0.08 to 1.78 ± 0.10 μM) but did not change compliance and renal perfusion flow (RPFF). In aged rats, relaxin did not affect any of the analyzed mesenteric or renal parameters. In aged compared with young placebo-treated rats, all mesenteric characteristics were comparable, while RPFF was lower (17%, from 6.9 ± 0.2 to 5.7 ± 0.1 ml·min⁻¹·100 g⁻¹) even though NO availability was comparable. Rxfp1 expression was not different among young and aged rats. Our findings suggest that moderate aging involves normal endothelial function but blunts the physiological endothelium-dependent and -independent vasodilator response to relaxin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21335472     DOI: 10.1152/ajpheart.00360.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  10 in total

Review 1.  Effects of relaxin on arterial dilation, remodeling, and mechanical properties.

Authors:  Kirk P Conrad; Sanjeev G Shroff
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

Review 2.  Vascular actions of relaxin: nitric oxide and beyond.

Authors:  C H Leo; M Jelinic; H H Ng; S A Marshall; J Novak; M Tare; K P Conrad; L J Parry
Journal:  Br J Pharmacol       Date:  2016-09-30       Impact factor: 8.739

3.  Differential effects of relaxin deficiency on vascular aging in arteries of male mice.

Authors:  Maria Jelinic; Marianne Tare; Kirk P Conrad; Laura J Parry
Journal:  Age (Dordr)       Date:  2015-06-25

Review 4.  Function and regulation of large conductance Ca(2+)-activated K+ channel in vascular smooth muscle cells.

Authors:  Xiang-Qun Hu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2012-04-13       Impact factor: 7.851

5.  Relaxin Attenuates Organ Fibrosis via an Angiotensin Type 2 Receptor Mechanism in Aged Hypertensive Female Rats.

Authors:  Giannie Barsha; Sarah L Walton; Edmund Kwok; Katrina M Mirabito Colafella; Anita A Pinar; Lucinda M Hilliard Krause; Tracey A Gaspari; Robert E Widdop; Chrishan S Samuel; Kate M Denton
Journal:  Kidney360       Date:  2021-09-10

6.  Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.

Authors:  Maria Jelinic; Chen-Huei Leo; Emiel D Post Uiterweer; Shaun L Sandow; Jonathan H Gooi; Mary E Wlodek; Kirk P Conrad; Helena Parkington; Marianne Tare; Laura J Parry
Journal:  FASEB J       Date:  2013-09-13       Impact factor: 5.191

7.  Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin).

Authors:  C H Leo; M Jelinic; H H Ng; M Tare; L J Parry
Journal:  Br J Pharmacol       Date:  2016-02-17       Impact factor: 8.739

8.  A vasoactive role for endogenous relaxin in mesenteric arteries of male mice.

Authors:  Chen Huei Leo; Maria Jelinic; Jon H Gooi; Marianne Tare; Laura J Parry
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

Review 9.  Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Laura J Parry; Rebecca H Ritchie
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

10.  Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.

Authors:  David Corcoran; Aleksandra Radjenovic; Ify R Mordi; Sheraz A Nazir; Simon J Wilson; Markus Hinder; Denise P Yates; Surendra Machineni; Jose Alcantara; Margaret F Prescott; Barbara Gugliotta; Yinuo Pang; Niko Tzemos; Scott I Semple; David E Newby; Gerry P McCann; Iain Squire; Colin Berry
Journal:  Cardiovasc Res       Date:  2021-01-01       Impact factor: 10.787

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.